FDA has issued draft guidance on "Oversight of Clinical Investigations: A Risk-Based Approach to Monitoring." The guidance document is now available from the FDA's web site using the following web link:
The new draft guidance is being issued to assist sponsors of clinical investigations in developing risk-based monitoring strategies and plans for clinical investigations of human drug and biological products, medical devices, and combinations thereof. This guidance is intended to make clear that sponsors can use a variety of approaches to meet their monitoring responsibilities during clinical investiations. This guidance describes a modern, risk-based approach to monitoring that focuses on critical study parameters and relies on a combination of monitoring activities to effectively oversee a study.
Comments to this draft guidance are due by November 28, 2011.
| 
